Bayban’s Bristol-Myers Squibb BMY Stock Holding History

Bayban’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.1K	Hold	575	–	–	0.03%	288
2026 Q1	$34.9K	Hold	575	–	–	0.03%	276
2025 Q4	$31K	Buy	+575	New	+$27.7K	0.03%	278

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bayban's BMY Position: Q2 2026 in Review

Bayban held its Bristol-Myers Squibb (BMY) position steady in Q2 2026 at 575 shares worth $33.1K. The position accounts for 0.03% of the portfolio, ranked #288.

Bayban first reported a position in BMY in Q4 2025 and has held it in 3 quarters since. The position peaked at $34.9K in Q1 2026. 2,401 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Bayban held 575 shares of Bristol-Myers Squibb worth $33.1K as of Q2 2026.
Bayban left its Bristol-Myers Squibb share count unchanged in Q2 2026.
Bristol-Myers Squibb made up 0.03% of Bayban's portfolio in Q2 2026, its #288 holding.
Bayban first reported a position in Bristol-Myers Squibb in Q4 2025 and has held it in 3 quarters since.
Bayban's Bristol-Myers Squibb position peaked at $34.9K in Q1 2026.
2,401 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Bayban's 13F filing for Q2 2026, filed 30 Jul 2026.